Monoclonal antibody therapies against SARS-CoV-2
Monoclonal antibody therapies against SARS-CoV-2
D. Focosi,S. McConnell,3 Authors,M. Tuccori
TLDR
It is shown how the omicron (B.1.529) variant of concern has reset treatment strategies so far, future developments that could lead to improved outcomes are discussed and the intrinsic limitations of using mAbs as therapeutic agents are reported.
Abstract
Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs and their effect as therapeutics in the pandemic, including structural classification, outcomes in clinical trials that led to the authorisation of mAbs, and baseline and treatment-emergent immune escape. We show how the omicron (B.1.1.529) variant of concern has reset treatment strategies so far, discuss future developments that could lead to improved outcomes, and report the intrinsic limitations of using mAbs as therapeutic agents.